| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥3.9B | ¥4.7B | -17.8% |
| Operating Income | ¥-6.2B | ¥-12.1B | +48.8% |
| Ordinary Income | ¥-6.3B | ¥-12.3B | +48.7% |
| Net Income | ¥-6.2B | ¥-13.4B | +53.5% |
| ROE | -43.3% | -182.7% | - |
FY2025 consolidated results: Revenue ¥3.9B (YoY -17.8%), Operating Loss ¥-6.2B (loss narrowed 48.8%), Ordinary Loss ¥-6.3B (loss narrowed 48.7%), Net Loss ¥-6.2B (loss narrowed 53.5%). The company operates a single-segment drug discovery business and recorded losses for the period, though the magnitude of losses decreased significantly from the prior year. The gross profit margin remained high at 90.1%, but SG&A expenses of ¥9.7B exceeded revenue by 2.5 times, resulting in an operating margin of -159.9%. Cash and deposits increased ¥5.8B to ¥17.1B, driven primarily by financing activities including bond issuance of ¥6.6B. Basic EPS improved from ¥-36.74 to ¥-13.19, reflecting the narrowed net loss. The company forecasts continued revenue decline to ¥3.0B with an operating loss of ¥-7.8B for the current fiscal year.
Revenue declined 17.8% YoY to ¥3.9B, driven by a geographic revenue breakdown showing Netherlands at ¥327M (down from ¥335M), Japan at ¥60M (down sharply from ¥136M, -55.9%), and minimal other regions. The primary customer Dutch Ophthalmic Research Center International B.V. contributed ¥327M while Kowa Corporation contributed ¥60M, indicating high customer concentration with the top two customers accounting for virtually all revenue. The sharp decline in Japan sales from ¥136M to ¥60M represents a significant deteriorating trend in domestic market penetration. Cost of sales remained modest at ¥0.4B, maintaining a gross profit margin of 90.1%, indicating the product mix itself retains strong unit economics. However, SG&A expenses of ¥9.7B (representing 250.3% of revenue) and R&D expenses of ¥6.7B (173.1% of revenue) substantially exceeded revenue, reflecting the fixed cost structure typical of early-stage drug discovery companies with ongoing development programs. Operating loss narrowed from ¥-12.1B to ¥-6.2B, a 48.8% improvement, driven primarily by lower absolute SG&A expenses (prior year's SG&A would have been proportionally higher given the loss magnitude). Non-operating items contributed a net loss of ¥0.1B, comprising FX gains of ¥0.1B in non-operating income offset by interest expense of ¥0.1B and other non-operating expenses, resulting in ordinary loss of ¥-6.3B. Extraordinary losses of ¥0.6B further impacted net income, though the specific nature is not disclosed in the provided data. The gap between ordinary loss and net loss of approximately ¥0.1B includes extraordinary items and tax effects, which are relatively immaterial given the loss-making position. This represents a revenue down, profit up pattern, where despite revenue contraction, the magnitude of losses decreased substantially due to improved cost management relative to the revenue base.
[Profitability] Operating margin of -159.9% and net profit margin of -160.7% reflect the unprofitable operations driven by high fixed costs in SG&A and R&D relative to revenue. ROE of -43.3% indicates significant destruction of shareholder value, though this should be contextualized within the drug discovery business model where profitability typically materializes only after successful commercialization of pipeline assets. The gross margin of 90.1% demonstrates strong product-level economics once revenue is generated. [Cash Quality] Cash and deposits of ¥17.1B provide substantial liquidity, with coverage of short-term debt at 8.4x (cash ¥17.1B vs current liabilities ¥2.0B). Operating cash flow of ¥-4.9B represents 0.78x of net income, triggering a quality alert as cash outflow from operations does not fully align with accounting losses, suggesting working capital movements or non-cash items affecting the relationship. Free cash flow of ¥-5.0B indicates ongoing cash consumption from operations. [Investment Efficiency] Total asset turnover of 0.18x reflects low revenue generation relative to the asset base of ¥21.7B, typical for R&D-intensive businesses with substantial cash holdings and limited revenue-generating assets. The capex-to-depreciation ratio of 0.06x signals potential investment underallocation, with capex of only ¥0.03B versus depreciation of ¥0.5B. [Financial Health] Equity ratio of 66.2% indicates a conservative capital structure with ample equity cushion. Current ratio of 990.8% provides exceptional short-term liquidity. Debt-to-equity ratio of 0.35x (long-term loans ¥5.1B vs equity ¥14.3B) remains manageable, though the company carries bonds payable of ¥3.0B. Interest coverage is deeply negative at approximately -70x, driven by negative EBIT, though absolute interest expense remains modest at ¥0.1B.
Operating cash flow of ¥-4.9B improved 62.0% YoY from ¥-12.9B, though it remains negative and represents 0.78x of net income, indicating cash outflows from operations exceed accounting losses after adjusting for non-cash items. The operating CF before working capital changes stood at ¥-4.8B, with working capital providing marginal relief through inventory reduction of ¥0.2B and receivables collection of ¥0.3B. Days sales outstanding of 89 days exceeds healthy thresholds, suggesting extended collection cycles. Investing cash flow of ¥-0.02B was minimal, with capex of only ¥0.03B substantially below depreciation of ¥0.5B, yielding a capex-to-depreciation ratio of 0.06x and signaling potential underinvestment in fixed assets. Free cash flow of ¥-5.0B reflects the ongoing cash consumption from operations without significant investment outlays. Financing cash flow of ¥10.8B provided substantial inflows, driven by bond issuance activities and long-term borrowing that more than offset bond redemptions and repayments, resulting in net cash increase. The financing activities enabled the ¥5.8B increase in cash and deposits to ¥17.1B, securing near-term liquidity despite negative operating cash flow. Interest paid of ¥0.1B remains modest relative to the cash position, maintaining financial flexibility.
Ordinary loss of ¥-6.3B versus operating loss of ¥-6.2B shows a non-operating net negative contribution of approximately ¥0.1B. Non-operating income of ¥0.1B comprised primarily FX gains of ¥0.1B and minimal interest income of ¥0.02B, while non-operating expenses of ¥0.2B consisted mainly of interest expense of ¥0.1B. The net non-operating impact is immaterial, representing approximately 2.6% of revenue. Extraordinary losses of ¥0.6B further reduced net income, though the specific nature and recurrence likelihood are not disclosed in the provided data. Operating cash flow of ¥-4.9B relative to net loss of ¥-6.2B yields an operating CF to net income ratio of 0.78x, triggering a quality alert as the cash outflow is proportionally smaller than the accounting loss. This suggests non-cash charges or working capital improvements partially offset the loss impact. The comprehensive income of ¥-6.3B closely tracks net income with negligible OCI adjustments, indicating limited unrealized gains or losses. Given the loss-making profile and negative operating cash flow, earnings quality concerns center on the sustainability of operations absent external financing, though the current cash position of ¥17.1B provides a substantial runway.
Progress rate versus full-year guidance shows revenue of ¥3.9B against forecast of ¥3.0B, representing 129.3% achievement, which exceeds expectations and suggests the forecast may be conservative or interim results have captured unusual timing of deliverables. Operating loss of ¥-6.2B versus forecast operating loss of ¥-7.8B represents 79.5% of the forecasted loss, indicating better-than-expected cost control or revenue performance to date. Net loss of ¥-6.2B versus forecast net loss of ¥-7.6B represents 81.1% of forecasted loss, similarly indicating more favorable results than anticipated. The forecast assumes revenue contraction of 22.6% YoY to ¥3.0B and an operating loss widening to ¥-7.8B from the current ¥-6.2B, suggesting management expects deteriorating operating conditions in subsequent periods despite the current period exceeding interim expectations. Forecasted EPS of ¥-14.75 implies continued losses per share, with no dividend forecast. The revenue guidance of ¥3.0B implies only ¥-0.9B of revenue in the remaining period if current results represent full-year outcomes, which appears inconsistent unless timing differences or one-time revenue in the current period are factored. The forecast notes reference business outlook assumptions on page 5 of supplementary materials, though specific assumptions are not detailed in the provided data.
Annual dividend is ¥0.00 with no interim dividend, maintaining a no-dividend policy consistent with the loss-making position. Dividend forecast for the upcoming period is also ¥0.00, indicating no near-term plans to initiate or resume dividend payments. Payout ratio is not calculable given negative net income. No share buyback activity is disclosed in the provided data. Total return ratio is 0% as no cash is being returned to shareholders through dividends or buybacks. The retention of all cash flows aligns with the need to fund ongoing R&D programs and operational losses, and the substantial cash position of ¥17.1B provides financial flexibility to continue operations without immediate dividend obligations.
Customer concentration risk remains elevated with the top customer Dutch Ophthalmic Research Center International B.V. contributing ¥327M (84.4% of revenue) and the second customer Kowa Corporation contributing ¥60M (15.5% of revenue), leaving minimal diversification. The sharp 55.9% decline in revenue from Kowa Corporation from ¥126M to ¥60M YoY indicates potential relationship strain or project completion, amplifying concentration risk. Operating cash flow consumption of ¥4.9B against cash reserves of ¥17.1B provides approximately 3.5 years of runway at current burn rates, though continued losses without revenue growth necessitate additional financing or operational turnaround within this horizon. The business model's inherent drug discovery risk, where pipeline success is uncertain and monetization timelines are extended, creates significant execution risk, with no disclosed milestone payments or license income evident in the current revenue composition to derisk the pipeline.
[Industry Position] (Reference - Proprietary Analysis)
The company operates in the pharmaceutical drug discovery sector, characterized by high R&D intensity, extended development timelines, and binary outcome risks from clinical trials. As a loss-making entity with negative operating margin of -159.9%, the company is positioned in the early-stage development phase typical of pre-commercial biotech ventures. Revenue of ¥3.9B and market capitalization metrics would place it in the small-cap segment. Comparative analysis is limited by the absence of multi-company industry benchmark data in the provided dataset. However, observable characteristics include an R&D expense ratio of 173.1% of revenue, substantially above sustainable levels for commercial-stage pharmaceutical companies but consistent with discovery-stage biotechs prioritizing pipeline development over near-term profitability. The gross margin of 90.1% aligns with high-margin pharmaceutical product economics, though absolute revenue remains modest. Customer concentration with two customers representing nearly 100% of revenue is atypical even for specialty pharma companies and represents a structural vulnerability. The equity ratio of 66.2% and cash position of ¥17.1B against total assets of ¥21.7B suggest a financially conservative posture relative to leveraged biotech peers. Operating cash flow burn and negative free cash flow are consistent with the sector's funding-intensive development phase. Industry positioning suggests the company is in a critical transition phase where pipeline advancement and revenue diversification are essential to achieving sustainable operations.
Key Takeaways from Earnings: First, the company demonstrated improved loss control with operating loss narrowing 48.8% YoY to ¥-6.2B despite revenue declining 17.8%, indicating material cost management progress, though absolute profitability remains distant. Second, cash and deposits increased substantially by ¥5.8B to ¥17.1B through financing activities including ¥6.6B in bond issuance net of redemptions, extending the operational runway to approximately 3.5 years at current cash burn rates, providing near-term financial stability. Third, customer concentration intensified with Dutch Ophthalmic Research Center representing 84.4% of revenue while Kowa Corporation's contribution declined 55.9% YoY from ¥126M to ¥60M, creating a structural risk where revenue sustainability hinges on a single relationship. Fourth, the operating cash flow to net income ratio of 0.78x and negative free cash flow of ¥-5.0B indicate that losses are translating into cash consumption, necessitating continued external funding or operational inflection to positive cash generation. Fifth, intangible assets declined 94.7% from ¥0.44B to ¥0.02B while retained earnings improved dramatically from ¥-37.3B to ¥-5.4B, suggesting accounting adjustments or capital restructuring that warrant detailed disclosure review to understand the economic substance versus book treatment. The combination of extended runway, improved cost control, but persistent customer concentration and cash consumption defines the current financial profile, with pipeline advancement and revenue diversification representing critical inflection points for long-term viability.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.